| 1 |
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12): 1090-1101.
|
| 2 |
Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications StudyⅡ[J]. Diabetes,1990, 39(9): 1116-1124.
|
| 3 |
Klein R, Klein BE, Moss SE. The Wisconsin epidemiologic study of diabetic retinopathy: an update [J]. Aust N Z J Ophthalmol,1990, 18(1): 19-22.
|
| 4 |
Pang C, Jia L, Jiang S, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study [J].Diabetes Metab Res Rev, 2012, 28(3): 276-283.
|
| 5 |
Chen H, Zheng Z, Huang Y, et al. A Microalbuminuria Threshold to Predict the Risk for the Development of Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients [J]. Plos One, 2012, 7(5):e36718.
|
| 6 |
Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) [J]. Kidney Int, 2003, 63(1): 225-232.
|
| 7 |
Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial[J]. JAMA, 1997, 278(23): 2069-2074.
|
| 8 |
Jia W, Gao X, Pang C, et al. Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS) [J]. Nephrol Dial Transplant, 2009, 24(12): 3724-3731.
|
| 9 |
Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study [J]. Diabetologia, 1996, 39(11): 1377-1384.
|
| 10 |
Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee [J]. Diabetes Care, 1997, 20(5): 836-843.
|
| 11 |
Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study [J]. Diabetes,1989, 38(11): 1456-1461.
|
| 12 |
Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group [J].Diabetes, 1988, 37(4): 476-481.
|
| 13 |
Adler AI, Boyko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study [J]. Diabetes Care, 1997, 20(7): 1162-1167.
|
| 14 |
Liu F, Bao Y, Hu R, et al. Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicentre survey in 12 city hospitals of China [J]. Diabetes Metab Res Rev, 2010, 26(6): 481-489.
|
| 15 |
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [J]. N Engl J Med, 1993, 329(14): 977-986.
|
| 16 |
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group [J]. Kidney Int, 1995, 47(6): 1703-1720.
|
| 17 |
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J].N Engl J Med, 2008, 358(24): 2560-2572.
|
| 18 |
The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group [J]. Ann Intern Med, 1995,122(8): 561-568.
|
| 19 |
Toyry JP, Niskanen LK, Mantysaari MJ, et al. Occurrence,predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis [J]. Diabetes,1996, 45(3): 308-315.
|
| 20 |
Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus [J]. N Engl J Med, 1995, 333(2): 89-94.
|
| 21 |
Henricsson M, Nilsson A, Janzon L, et al. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus [J]. Diabet Med, 1997,14(2): 123-131.
|
| 22 |
Kostraba JN, Dorman JS, Orchard TJ, et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects [J]. Diabetes Care, 1989, 12(10):686-693.
|
| 23 |
Cahill M, Halley A, Codd M, et al. Prevalence of diabetic retinopathy in patients with diabetes mellitus diagnosed after the age of 70 years [J]. Br J Ophthalmol, 1997, 81(3): 218-222.
|
| 24 |
Krolewski AS, Laffel LM, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus [J]. N Engl J Med, 1995,332(19): 1251-1255.
|
| 25 |
Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus [J].Lancet, 1998, 351(9095): 28-31.
|
| 26 |
Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme [J]. Eye (Lond), 2010, 24(1): 1-6.
|
| 27 |
Decleves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes [J]. Nat Rev Nephrol, 2010,6(6): 371-380.
|
| 28 |
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [J]. Lancet, 2005, 366(9500): 1849-1861.
|
| 29 |
Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study [J].Diabetologia, 2011, 54(2): 280-290.
|
| 30 |
Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial [J]. Lancet, 2007, 370(9600):1687-1697.
|
| 31 |
Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes [J]. N Engl J Med, 2010, 363(3): 233-244.
|
| 32 |
Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial [J].Ophthalmology, 2009, 116(10): 1943-1948.
|
| 33 |
Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial [J]. Diabetes Care,2011, 34(9): 2054-2060.
|
| 34 |
Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study [J]. Diabetes Res Clin Pract, 2001, 52(3): 175-183.
|
| 35 |
Kanter M, Sen S, Donmez S, et al. Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats[J]. Ren Fail, 2010, 32(4): 498-505.
|